Chemotherapy with bevacizumab (BV) +modified FOLFOX6 for unresectable colorectal cancer
Matsumoto, R.; Kuroda, T.; Yamada, H.; Hasegawa, K.; Mamiya, Y.; Kon, A.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2207-2209
2009
ISSN/ISBN: 0385-0684 PMID: 20037372 Document Number: 632595
We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients: liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.
Document emailed within 1 workday
Related Documents
Maruo, H.; Suzuki, K.; Ishikawa, S.; Murakami, T.; Higashi, Y.; Shoji, T.; Yamazaki, M.; Taniguchi, M.; Nishiyama, R. 2014: Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(13): 2583-2586Arakawa, S.; Horiguchi, A.; Tomishige, H.; Kawabe, N.; Nagata, H.; Ishihara, S.; Ito, M.; Asano, Y.; Ito, R.; Isetani, M.; Shimizu, K.; Kamio, K.; Kawai, T.; Yasuoka, H.; Imaeda, Y. 2018: Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 45(4): 649-651
Sagawa, T.; Sato, Y.; Takayama, T.; Kuroda, H.; Hirakawa, M.; Abe, S.; Iyama, S.; Sakamaki, S.; Kato, J.; Niitsu, Y. 2007: Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6 Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(9): 1467-1471
Shitara, K.; Munakata, M.; Muto, O.; Kasai, M.; Okada, R.; Mitobe, S.; Sakata, Y. 2007: Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1079-1084
Koshiishi, H.; Park, S.; Matsuyama, T.; Goto, H.; Kakimoto, Y.; Sakamoto, K.; Nishida, K.; Okamura, T.; Minami, T.; Kato, H.; Maruyama, M.; Takahashi, E.; Koshiishi, Y. 2009: Two resected cases of pulmonary metastasis from post operative colorectal cancer after preoperative chemotherapy with FOLFOX Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(12): 2201-2203
Soga, Y.; Ito, D.; Asano, H.; Go, M.; Iwai, M.; Okada, K.; Matsuoka, T.; Adachi, S.; Usami, E.; Kimura, M.; Nakao, T.; Yoshimura, T.; Yasuda, T.; Ogawa, T.; Iwaki, A. 2013: Continuation of chemotherapy with bevacizumab for advanced and recurrent colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 40(10): 1341-1345
Iwasa, S.; Shimada, Y. 2011: Treatment strategy of chemotherapy for unresectable metastatic or recurrent colorectal cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 69(Suppl 3): 427-432
Takeda, T.; Miyake, M.; Tanaka, K.; Uemura, M.; Ikeda, M.; Maeda, S.; Yamamoto, K.; Hama, N.; Nishikawa, K.; Miyamoto, A.; Miyazaki, M.; Hirao, M.; Nakamori, S.; Sekimoto, M. 2015: XELOX plus Bevacizumab Chemotherapy for a Patient with Postoperative Recurrence of Colorectal Cancer Under Hemodialysis for Chronic Renal Failure Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(12): 1594-1596
Katayose, Y.; Yamamoto, K.; Nakagawal, K.; Takemura, S.; Takahashi, M.; Nakamura, R.; Shimamura, H.; Rikiyama, T.; Egawa, S.; Yoshda, H.; Motoi, F.; Naitoh, T.; Unno, M. 2015: Feasibility Assessment of Modified FOLFOX-6 as adjuvant treatment after resection of liver metastases from colorectal cancer: analyses of a multicenter phase II clinical trial (Miyagi-HBPCOG Trial-001) Hepato-Gastroenterology 62(138): 303-308
Yoshimura, K.; Hazama, S.; Iizuka, N.; Takano, N.; Matsuoka, K.; Tangoku, A.; Oka, M. 2002: Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2117-2120
Kobayashi, H.; Uetake, H.; Higuchi, T.; Enomoto, M.; Iida, S.; Ishikawa, T.; Ishiguro, M.; Kato, S.; Matsuyama, T.; Ono, H.; Yamauchi, S.; Masuda, D.; Sugihara, K. 2011: Repeated resections for originally unresectable liver metastasis from colorectal cancer after multiagent chemotherapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(12): 2301-2303
Imaizumi, H.; Ishibashi, K.; Okada, N.; Tajima, Y.; Amano, K.; Hatano, S.; Kuwabara, K.; Sobajima, J.; Ishiguro, T.; Ohsawa, T.; Kumamoto, K.; Kumagai, Y.; Haga, N.; Ishida, H. 2012: Clinical outcomes in refractory colorectal cancer patients with wild-type K-ras treated with bevacizumab and oxaliplatin-based chemotherapy as a first-line treatment Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(12): 2185-2188
Yamazoe, S.; Yamaguchi, K.; Terasawa, H.; Ojima, T.; Tsujimura, H.; Shimomura, T. 2011: A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(1): 125-128
Hotta, T.; Takifuji, K.; Arii, K.; Yokoyama, S.; Matsuda, K.; Higashiguchi, T.; Tominaga, T.; Oku, Y.; Yamaue, H. 2006: Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival Anticancer Research 26(2b): 1425-1432
Shitara, K.; Munakata, M.; Kudo, T.; Kasai, M.; Muto, O.; Okada, R.; Mitobe, S.; Ishiguro, A.; Sakuraba, H.; Ikami, I.; Sakata, Y. 2006: Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(13): 2033-2037
Klotz, H.P.; Weder, W.; Largiadèr, F. 1993: Local and systemic toxicity of intra-hepato-arterial chemotherapy for treatment of unresectable liver metastases of colorectal cancer with 5-Fluorouracil and high dose Leucovorin Helvetica Chirurgica Acta 60(1-2): 283-286
des Guetz, G.; Mariani, P.; Cucherousset, J.; Benamoun, M.; Lagorce, C.; Sastre, X.; Le Toumelin, P.; Uzzan, B.; Perret, G.Y.; Morere, J.F.; Breau, J.L.; Fagard, R.; Schischmanoff, P.O. 2007: Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer Anticancer Research 27(4c): 2715-2719
Tran, B.; McKendrick, J. 2010: Metastatic urachal cancer responding to FOLFOX chemotherapy Canadian Journal of Urology 17(2): 5120-5123
Huang, C.-x.; Li, Z.-y.; Jiang, Y.-q.; Duan, G.-l.; Wang, Q.-q. 2010: Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer Zhonghua Wei Chang Wai Ke Za Zhi 13(9): 661-663
Mizota, A.; Shitara, K.; Kondo, C.; Nomura, M.; Yokota, T.; Takahari, D.; Ura, T.; Muro, K. 2011: FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases Gan to Kagaku Ryoho. Cancer and ChemoTherapy 38(7): 1205-1208